You are here

  • Home
  • Archive
  • Volume 15, Issue 1
  • When one plus one means more than two: the blockade of both IL-4 and IL-13 inflammatory pathways with dupilumab in a case of severe refractory T2-high asthma

Article info

Article menu
Download PDFPDF
Case report
When one plus one means more than two: the blockade of both IL-4 and IL-13 inflammatory pathways with dupilumab in a case of severe refractory T2-high asthma

Authors

  • Carmelo Sofia Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Lazio, Italy PubMed articlesGoogle scholar articles
  • Jacopo Simonetti Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Lazio, Italy PubMed articlesGoogle scholar articles
  • Cristina Boccabella Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Lazio, Italy PubMed articlesGoogle scholar articles
  • Matteo Bonini Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Lazio, ItalyNational Heart and Lung Institute (NHLI), Imperial College London, London, UK PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Carmelo Sofia; carmelosofia93{at}gmail.com
View Full Text

Citation

Sofia C, Simonetti J, Boccabella C, et al
When one plus one means more than two: the blockade of both IL-4 and IL-13 inflammatory pathways with dupilumab in a case of severe refractory T2-high asthma
BMJ Case Reports CP 2022;15:e244503.

Publication history

  • Accepted December 5, 2021
  • First published January 17, 2022.
Online issue publication 
January 24, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.